vision history team
For over 200 years we’ve known that human health is cellular health. And yet, when it comes to decisions that impact human health, cellular health is rarely considered. The technologies available have not supported routine single cell analysis. This has far-reaching consequences for all of us: drug effects lack precision, preventive healthcare is largely absent, and accurate disease diagnoses come late if ever. Sampling Human is changing the status quo by bringing single cell technology that is scalable enough to bring access to cellular health worldwide.
Sampling Human is named for the ability to predict human outcomes from single cell samples. The company was founded in 2016 to elevate the field beyond genetic analysis to routinely provide complex single cell data.
Thanks to the backing of a prominent central European investment group BPD partners a.s. (Draslovka, DIANA biotech, Nanuncio, Ginkgo Bioworks, Scipher Medicine, Q2Pharma) as well as support from top Czech research institutions UWB and IOCB, SAMPLING has in its short existence developed a portfolio of single cell technologies that redefine the implications of single cell data in practice.
With follow-on support from the Czech Ministry of Industry, and in collaboration with the Charles University Hospital, SAMPLING is currently validating these technologies in clinical workflows.
Sampling Human harnesses global innovation potential with state-of-the-art facilities in San Francisco and Prague. In addition, we are connected to a network of clinical institutions and core facilities that give us the power to engineer, discover, and validate single cell technologies and biomarkers with unprecedented speed and depth.